Similar articles

• From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.

  Roukos DH, Papaloukas C, Tzaphlidou M. Roukos DH, et al. Future Oncol. 2013 Jan;9(1):5-8. doi: 10.2217/fon.12.169. Future Oncol. 2013. PMID: 23252557 No abstract available.
• [BRAF inhibitor and MEK inhibitor].

  Uhara H. Uhara H. Gan To Kagaku Ryoho. 2015 Apr;42(4):428-33. Gan To Kagaku Ryoho. 2015. PMID: 26020982 Japanese. No abstract available.
• Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare.

  Ibrahim T, Routier E, Weill A, Baz M, Robert C. Ibrahim T, et al. Eur J Cancer. 2017 Sep;82:25-26. doi: 10.1016/j.ejca.2017.05.039. Epub 2017 Jun 21. Eur J Cancer. 2017. PMID: 28646770 No abstract available.
• Targeted Therapy for Melanoma.

  Wong DJ, Ribas A. Wong DJ, et al. Cancer Treat Res. 2016;167:251-62. doi: 10.1007/978-3-319-22539-5_10. Cancer Treat Res. 2016. PMID: 26601866 Review.
• BRAF and MEK inhibition in melanoma.

  Dossett LA, Kudchadkar RR, Zager JS. Dossett LA, et al. Expert Opin Drug Saf. 2015 Apr;14(4):559-70. doi: 10.1517/14740338.2015.1011618. Epub 2015 Feb 4. Expert Opin Drug Saf. 2015. PMID: 25648338 Review.